Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why

Aldeyra Therapeutics’(ALDX) clinical-stage immunology pipeline comprises two candidates, reproxalap and ADX-629, which are undergoing late-stage and mid-stage development, respectively.The company’s lead product candidate, Reproxalap, is currently being evaluated in two separate phase III studies for dry eye disease and allergic conjunctivitis.Shares of Aldeyra rallied 43.3% in the past week, driven by the company’s clinical development plan announced on Mar 28, which is intended to enable the resubmission ...